0001437749-22-011992.txt : 20220512 0001437749-22-011992.hdr.sgml : 20220512 20220512070533 ACCESSION NUMBER: 0001437749-22-011992 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220512 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aravive, Inc. CENTRAL INDEX KEY: 0001513818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264106690 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36361 FILM NUMBER: 22915658 BUSINESS ADDRESS: STREET 1: RIVER OAKS TOWER STREET 2: 3730 KIRBY DRIVE, SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: 936-355-1910 MAIL ADDRESS: STREET 1: RIVER OAKS TOWER STREET 2: 3730 KIRBY DRIVE, SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Versartis, Inc. DATE OF NAME CHANGE: 20110223 8-K 1 arav20220307_8k.htm FORM 8-K arav20220307_8k.htm
false 0001513818 0001513818 2022-05-12 2022-05-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 12, 2022
Aravive, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
001-36361
26-4106690
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
River Oaks Tower
3730 Kirby Drive, Suite 1200
Houston, Texas 77098
(Address of principal executive offices)
 
(936) 355-1910
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common stock, par value $0.0001 per share
  
ARAV
  
Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02. Results of Operation and Financial Condition.
 
On May 12, 2022, Aravive, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
The following exhibit is furnished with this Current Report on Form 8-K:
 
Exhibit
  
Description
99.1
  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
 
       
Date: May 12, 2022
ARAVIVE, INC.
(Registrant)
  
     
 
By:
/s/ Vinay Shah
   
Name: Vinay Shah
Title: Chief Financial Officer
 
 
 EX-99.1 2 ex_344035.htm EXHIBIT 99.1 ex_344035.htm

Exhibit 99.1

logo.jpg

 

Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates

 

●

 Reported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCC

●

 Presented updated modeling data from batiraxcept clinical trials at the AACR annual meeting
● Dosed first patient in Phase 2 study of batiraxcept in clear cell Renal Cell Carcinoma
● Provided positive clinical updates on ongoing clinical programs at company’s KOL Symposium
● Appointed Scott Dove, Ph.D. as Chief Operating Officer

●

 Strengthened balance sheet with approximately $20 million from two separate transactions

 

Houston, TX, May 12, 2022 - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates.

 

“During the first quarter we continued to advance the development of batiraxcept for the potential treatment of ovarian, kidney and pancreatic cancer, successfully raised additional capital and strengthened the management team,” said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. “Our registrational Phase 3 trial of batiraxcept in ovarian cancer continues on pace to complete enrollment in 2022, with top line data anticipated in 2Q’23 and a potential BLA filing with the FDA in 4Q’23. Our ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma also continues to successfully enroll patients across three cohorts and the Phase 1b trial of batiraxcept in pancreatic cancer completed enrollment in 1Q’22. Updated results are anticipated throughout 2022. We remain encouraged by the continued signals of best-in-class potential of batiraxcept and look forward to providing continued clinical updates on each of our three active programs throughout 2022.”

 

 

Recent Corporate Highlights

●

Batiraxcept in Platinum Resistant Ovarian Cancer (PROC): The registration-directed Phase 3 program of batiraxcept in combination with paclitaxel in PROC remains on track to complete enrollment in 2H’22. Topline data from the trial is anticipated to be available in 2Q’23. CMC work related to the PROC program remains on track with the goal of filing a BLA in 4Q’23. The global, randomized, double-blind, placebo-controlled Phase 3 trial is evaluating efficacy and tolerability of batiraxcept at a dose of 15 mg/kg in combination with paclitaxel versus placebo in combination with paclitaxel. The trial aims to enroll 350 platinum resistant, high-grade serous ovarian cancer patients who have received 1-4 prior lines of therapy.

 

●

Batiraxcept in Clear Cell Renal Cell Carcinoma (ccRCC) and Serum-Based Biomarker: The Company dosed first patient in the Phase 2 study of batiraxcept in combination with cabozantinib in 2L+ ccRCC trial in January 2022. Enrollment across the three patient cohorts of the Phase 2 study continues on pace for planned completion and updated data releases during 2Q’22. The Company anticipates providing clinical updates on the Phase 2 study throughout 2022. In March 2022, the Company announced new biomarker data from the Phase 1b portion of the trial in patients with ccRCC. Aravive had previously reported an observable correlation of baseline levels of serum soluble AXL (sAXL)/GAS6 to clinical activity in its Phase 1b PROC trial. As such, one of the objectives of the ongoing Phase 1b/2 ccRCC trial is to evaluate the correlation of baseline sAXL/GAS6 with radiographic response in patients with ccRCC treated with batiraxcept plus cabozantinib. The Company continues to engage the US FDA about utilizing the biomarker as a basis for an accelerated development strategy. Updated biomarker data is anticipated in 2022.

 

As of April 30, 2022, 26 patients with ccRCC were treated with batiraxcept in the Phase 1b portion of the trial at doses of 15 mg/kg (n=16) and 20 mg/kg (n=10), plus cabozantinib 60 mg daily in previously treated (2L+) patients with ccRCC. There were no dose limiting toxicities observed at either dose and 14 of the 26 patients remain on study. The best overall response rate (ORR, confirmed + unconfirmed) in the ITT population was 46% and 50% in patients dosed with 15 mg/kg (the recommended Phase 2 dose). The best ORR in the biomarker high population was 60%, and 67% in the biomarker high population dosed at 15 mg/kg. The 7-month progression-free survival (PFS) rate was 71% in the ITT population, 83% in the biomarker high population, and 91% in the 15 mg/kg biomarker high group. Eight patients experienced resolution of one or more target lesions.  The company is on track to report additional updated results from the Phase 1b portion of the trial in the second quarter of 2022.

 

●

Batiraxcept in Pancreatic Adenocarcinoma: In January 2022, Aravive completed enrollment of the Phase 1b portion of its Phase 1b/2 trial of batiraxcept in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma who are eligible to receive gemcitabine and nab-paclitaxel combination therapy. As of May 3, 2022, 21 patients have been treated with 15 mg/kg batiraxcept in combination with gemcitabine and nab-paclitaxel as a first-line treatment. Batiraxcept has been generally well-tolerated with no unexpected safety signals. The best ORR (confirmed + unconfirmed) was 29%. As noted with the other programs, an observable correlation of baseline levels of serum soluble AXL (sAXL)/GAS6 to clinical activity was noted in this trial as well and the best ORR in the biomarker high population was 40%. Five patients experienced resolution of one or more target lesions; however, 2 of these patients have since progressed. The company is on track to report additional updated data from the Phase 1b portion of the trial in the second quarter of 2022.

 

 
 

 

●

Strengthened Balance Sheet: In January 2022, Aravive raised approximately $10.0 million from the sale of a pre-funded warrant to purchase 4,545,455 shares of the company’s common stock to Eshelman Ventures, LLC at a price of $2.20 per share, which was the consolidated closing bid price of the company’s common stock on The Nasdaq Global Select Market on December 31, 2021. Additionally, Fred Eshelman, Pharm.D., was appointed the Executive Chairman of Aravive, having served as the Non-Executive Chairman of the board since April 2020. In March 2022, the Company raised an additional approximately $10.0 million from the sale of common stock and a pre-funded warrant for an aggregate of a combination of 4,850,241 shares of the company’s common stock and pre-funded warrants to a single healthcare-focused institutional investor and Eshelman Ventures, LLC and issued warrants to purchase an additional aggregate of 4,850,241 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Combined, the additional capital infusions strengthen the Company’s financial position and fund operations as currently planned into 1Q’23.

 

First Quarter 2022 Financial Results

Revenue for the three months ended March 31, 2022 was $1.1 million compared with $0.3 million for the same period in 2021. Revenues were derived solely from the Company’s collaboration and license agreement with 3D Medicines, executed in November 2020 to develop and commercialize batiraxcept in oncology indications in Greater China. Revenues represent a portion of initial signing and milestone payments received from 3D Medicines that is recognized at the time of the receipt and a portion of the payments that is deferred and recognized over the PROC trial period.

 

Total operating expenses for the three months ended March 31, 2022 were $16.1 million compared with $8.3 million for the same period in 2021. Total operating expenses for the three months ended March 31, 2022 included non-cash stock-based compensation expense of $0.6 million, compared to $0.5 million for the same period in 2021.

 

For the three months ended March 31, 2022, Aravive reported a net loss of $13.1 million, or $0.62 per share compared to a net loss of $8.0 million, or $0.44 per share for the same period in 2021.

 

Cash Position

As of March 31, 2022, cash and cash equivalents were $65.8 million, compared to $59.4 million as of December 31, 2021. In January 2022, Aravive announced an approximately $10.0 million investment by Eshelman Ventures and in March 2022, Aravive announced an additional approximately $10 million investment by a healthcare-focused institutional investor and Eshelman Ventures, LLC. The company anticipates that its current cash and cash equivalents will fund operating plans into 1Q’23.

 

 
 

 

About Aravive

Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com.

 

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions and include statements regarding the registrational Phase 3 trial of batiraxcept in ovarian cancer continuing on pace to complete enrollment in 2022, with top line data anticipated in 2Q’23 and a potential BLA filing with the FDA in 4Q’23, the ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma also continuing to successfully enroll patients across three cohorts; updated results are anticipated throughout 2022, providing continued clinical updates on each of our three active programs throughout 2022, the Phase 3 trial enrolling 350 platinum resistant, high-grade serous ovarian cancer patients who have received 1-4 prior lines of therapy, the potential of utilizing the biomarker as a basis for an accelerated development strategy for clear cell renal cell carcinoma; updated biomarker data in 2022, being on track to report additional updated results from the Phase 1b portion of the clear cell renal cell carcinoma trial in the second quarter of 2022, being on track to report additional updated data from the Phase 1b portion of the pancreatic adenocarcinoma trial in the second quarter of 2022 and current cash and cash equivalents funding operating plans into 1Q’23. Forward-looking statements are based on current beliefs and assumptions, are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement as a result of various factors, including, but not limited to, risks and uncertainties related to: the ability to report data from the current clinical trials in accordance with current timelines, the data from patients treated in the future with batiraxcept being consistent with the results reported, the ability to enroll the expected number of patients, the impact of COVID-19 on the Company's clinical strategy, clinical trials, supply chain and fundraising, the Company's ability to expand development into additional indications, the Company's dependence upon batiraxcept, batiraxcept’s ability to have favorable results in clinical trials and ISTs, the clinical trials of batiraxcept having results that are as favorable as those of preclinical and clinical trials, the ability to receive regulatory approval, potential delays in the Company's clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients; the risk that batiraxcept may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that the Company may encounter difficulties in manufacturing batiraxcept; if batiraxcept is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing the Company's intellectual property rights; the Company's reliance on its licensor of intellectual property and financing needs. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, recent Current Reports on Form 8-K and subsequent filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 

 
 

 

Aravive, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 

   

Three Months Ended

  
   

March 31,

  
   

2022

    

2021

  
    (unaudited)  

Revenue

                

Collaboration revenue

   $ 1,092     $ 256  

Total revenue

     1,092       256  

Operating expenses

                

Research and development

     13,002       5,884  

General and administrative

     3,088       2,380  

Total operating expenses

     16,090       8,264  

Loss from operations

     (14,998 )     (8,008 )

Other income (expense), net

     1,941       4  

Net loss

   $ (13,057 )   $ (8,004 )

Net loss per share- basic and diluted

   $ (0.62 )   $ (0.44 )

Weighted-average common shares used to compute basic and diluted net loss per share

     21,130       18,067  

 

 
 

 

Aravive, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

 

   

March 31,

    

December 31,

  
   

2022

    

2021

  
   

(unaudited)

          

Assets:

                

Cash and cash equivalents

   $ 65,825     $ 59,424  

Restricted cash

     2,431       2,431  

Other assets

     3,595       3,725  

Operating lease right-of-use assets

     2,020       2,207  

Total assets

   $ 73,871     $ 67,787  

Liabilities and stockholders' equity:

                

Accounts payable and accrued liabilities

   $ 13,086     $ 11,073  

Deferred revenue

     7,027       8,119  

Operating lease obligation

     5,787       6,373  

Warrant liability

     8,772       —  

Total liabilities

     34,672       25,565  

Total stockholders' equity

     39,199       42,222  

Total liabilities and stockholders’ equity

   $ 73,871     $ 67,787  

 

 

Contact:

Marek Ciszewski, J.D.

Vice President, Investor Relations

Marek@Aravive.com

(562) 373-5787

 

 
 EX-101.SCH 3 arav-20220512.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 arav-20220512_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 arav-20220512_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 arav-20220512_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 logo.jpg begin 644 logo.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information
May 12, 2022
Document Information [Line Items]  
Entity, Registrant Name Aravive, Inc.
Document, Type 8-K
Document, Period End Date May 12, 2022
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36361
Entity, Tax Identification Number 26-4106690
Entity, Address, Address Line One River Oaks Tower
Entity, Address, Address Line Two 3730 Kirby Drive, Suite 1200
Entity, Address, City or Town Houston
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 77098
City Area Code 936
Local Phone Number 355-1910
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol ARAV
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001513818

XML 9 arav20220307_8k_htm.xml IDEA: XBRL DOCUMENT 0001513818 2022-05-12 2022-05-12 false 0001513818 8-K 2022-05-12 Aravive, Inc. DE 001-36361 26-4106690 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston TX 77098 936 355-1910 false false false false Common stock ARAV NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.arav.com/20220512/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports arav20220307_8k.htm arav-20220512.xsd arav-20220512_def.xml arav-20220512_lab.xml arav-20220512_pre.xml ex_344035.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "arav20220307_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "arav-20220512_def.xml" ] }, "inline": { "local": [ "arav20220307_8k.htm" ] }, "labelLink": { "local": [ "arav-20220512_lab.xml" ] }, "presentationLink": { "local": [ "arav-20220512_pre.xml" ] }, "schema": { "local": [ "arav-20220512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "arav", "nsuri": "http://www.arav.com/20220512", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "arav20220307_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.arav.com/20220512/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "arav20220307_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity, Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.arav.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001437749-22-011992-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-011992-xbrl.zip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�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